Opthea Limited
Opthea is Biotechnology company with headquarters is in Australia.
Opthea is committed to improving vision in patients suffering from retinal eye diseases.
They are developing a novel therapeutic called OPT-302, a VEGF-C/D ‘trap’, to be used in conjunction with existing standard of care anti-VEGF-A therapies.